Sunesis Pharmaceuticals Inc (NASDAQ:SNSS)

2.83
Delayed Data
As of Apr 20
 +0.06 / +2.17%
Today’s Change
1.82
Today|||52-Week Range
7.69
-23.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$145.2M

Company Description

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

Contact Information

Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard
South San Francisco California 94080
P:(650) 266-3500
Investor Relations:

Employees

Shareholders

Other institutional38.91%
Individual stakeholders14.89%
Mutual fund holders10.86%

Top Executives

Dayton MisfeldtChief Executive Officer & Director
Willie QuinnCFO & VP-Finance & Corporate Development
Judith A. FoxChief Scientific Officer
Gene C. JamiesonVice President-Technical Operations
Jennifer A. SmithVice President-Biometrics